company? Let’s change
that.
Don't see your company?
Create a company profileThe advent of multi-modal data collections has unlocked an opportunity for in-depth and multi-faceted data analytics. However, it has also enforced a clear need for better data management and surveillance along with the reliable reproducibility of such analytics. Managing modern data clusters in an active and thriving business paradigm requires a stringent and reliant framework structure that is both scalable and flexible to change with the course of an ever-evolving and competitive field. Sonrai Analytics’s software platform is unique in this context, as it is designed to meet the demands of both precision analytics and reproducible data findings of an important legacy. Powerful and versatile analytics can harness the ‘data lake’ that is being generated in all successful business models, to discover new and optimised approaches, and retire redundant methods. In a constantly evolving biomedical data landscape, we at Sonrai Analytics help you conceptualise your raw data into actionable insights.
For almost 200 years, Dun & Bradstreet has helped clients and partners grow and thrive through the power of data, analytics, and data-driven solutions. Our more than 6,000 employees around the world are dedicated to this unique purpose, and we are guided by important values that make us the established leader in business decisioning data and analytical insights. Our data & insights are valuable at all phases of a business lifecycle and whatever the economic environment.
BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, having discovered a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.
Smart, sustainable alternative to OPC, made using data and machine learning algorithms.
Work Your Passion. Live Your Purpose.